中国临床药理学杂志Issue(10)：790-792,3.DOI:10.13699/j.cnki.1001-6821.2015.10.007
瑞舒伐他汀与阿托伐他汀对急性心肌梗死患者的临床疗效与安全性评价
Efficacy and safety of rosuvastatin and atorvastatin in acute myocardial infarction patients
潘永东 1宋炳慧 1王书清 1谢广宇1
作者信息
- 1. 齐齐哈尔市第一医院 心内一科，黑龙江 齐齐哈尔 161005
- 折叠
摘要
Abstract
Objective To evaluate the efficacy and safety of rosuvastatin and atorvastatin in acute myocardial infarction ( AMI ) , and its therapy compliance and tolerance of long -time medication.Methods A total of 120 patients with AMI who were willing to receive percutaneous coronary intervention ( PCI) were enrolled and divided into rosuvastatin group ( n=60) and atorvastatin group(n=60).Total cholesterol(TC), triglyceride ( TG ) , low density liporotein -cholesterol ( LDL -C ) , high density lipoprotein cholesterol ( HDL-C) , high-sensitivity C -reactive protein ( hs -CRP ) , interleukin -8 ( IL -8 ) , tumor necrosis factor -α( TNF-α) were observed before and 6 months after surgery. Stent restenosis and major adverse cardiac events ratio were recorded . Results TC, TG, LDL-C, hs-CRP, IL-8, TNF-αin rosuvastatin group was lower than that in atorvastatin group ( P<0.05 ).HDL-C was higher than atorvastatin group ( P<0.05 ) and its compliance was better than atorvastatin group (P<0.05).The incidence of angina was signifi-cantly lower than the atorvastatin group (P<0.05).The tolerance of two groups had no significant difference ( P >0.05 ) .Conclusion Rosu-vastatin has a better lipid and anti-inflammatory effect than atorvastatin . It also can reduce the incidence of stenocardia and restenosis .关键词
瑞舒伐他汀/阿托伐他汀/急性心肌梗死/C -反应蛋白/白细胞介素-8/肿瘤坏死因子-αKey words
rosuvastatin/atorvastatin/acute myocardial infarction/C-reactive protein/interleukin-8/tumor necro-sis factor-α分类
医药卫生引用本文复制引用
潘永东,宋炳慧,王书清,谢广宇..瑞舒伐他汀与阿托伐他汀对急性心肌梗死患者的临床疗效与安全性评价[J].中国临床药理学杂志,2015,(10):790-792,3.
